1 |
X. Zhang, M. Sun, A. Zheng, D. Cao, Y. Bi, J. Sun, Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration, Eur. J. Pharm. Sci., 45, 632-638 (2012).
DOI
|
2 |
E. Locatelli, M. C. Franchini, Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system, J. Nanoparticle Res., 14, 1316 (2012).
DOI
|
3 |
M. A. Moses, H. Brem, R. Langer, Advancing the field of drug delivery: taking aim at cancer, Cancer Cell, 4, 337-341 (2003).
DOI
|
4 |
M. M. Badran, A. H. Alomrani, G. I. Harisa, A. E. Ashour, A. Kumar, A. E. Yassin, Novel docetaxel chitosan-coated PLGA/PCL nanoparticles with magnified cytotoxicity and bioavailability, Biomed. Pharmacother., 106, 1461-1468 (2018).
DOI
|
5 |
D. Ding, Q. Zhu, Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics, Mater. Sci. Eng., C, 92, 1041-1060 (2018).
DOI
|
6 |
N. K. Al-Nemrawi, A. R. Okour, R. H. Dave, Surface modification of PLGA nanoparticles using chitosan: Effect of molecular weight, concentration, and degree of deacetylation, Adv. Polym. Technol., 37, 3066-3075 (2018).
DOI
|
7 |
L. Hu, X. Meng, R. Xing, S. Liu, X. Chen, Y. Qin, H. Yu, P. Li, Design, synthesis and antimicrobial activity of 6-N-substituted chitosan derivatives, Bioorg. Med. Chem. Lett., 26, 4548-4551 (2016).
DOI
|
8 |
A. Zimoch-Korzycka, L. Bobak, A. Jarmoluk, Antimicrobial and antioxidant activity of chitosan/hydroxypropyl methylcellulose film-forming hydrosols hydrolyzed by cellulase, Int. J. Mol. Sci., 17, 1436 (2016).
DOI
|
9 |
M. P. Patel, R. R. Patel, J. K. Patel, Chitosan mediated targeted drug delivery system: a review, J. Pharm. Pharm., 13, 536-557 (2010).
DOI
|
10 |
B. Semete, L. Booysen, L. Kalombo, J. D. Venter, L. Katata, B. Ramalapa, J. A. Verschoor, H. Swai, In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles, Toxicol. Appl. Pharmacol., 249, 158-165 (2010).
DOI
|
11 |
P. Colucci, C. S. Yue, M. Ducharme, S. Benvenga, A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism, Eur. Endocrinol., 9, 40 (2013).
|
12 |
M. Goldberg, I. Gomez-Orellana, Challenges for the oral delivery of macromolecules, Nat. Rev. Drug Discov., 2, 289-295 (2003).
DOI
|
13 |
R. Duncan, H. Ringsdorf, R. Satchi-Fainaro, Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: past, present and future opportunities, J. Drug Target., 14, 337-341 (2006).
DOI
|
14 |
E. W. Ng, D. T. Shima, P. Calias, E.T . Cunningham, D.R. Guyer, A.P. Adamis, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov., 5, 123-132 (2006).
DOI
|
15 |
Y. Yun, Y. W. Cho, K. Park, Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery, Adv. Drug Deliv. Rev., 65, 822-832 (2013).
DOI
|
16 |
N. Krinick, Y. Sun, D. Joyner, J. Spikes, R. Straight, J. Kopecek, A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light, J. Biomater. Sci., 5, 303-324 (1994).
DOI
|
17 |
G.-W. Jeong, S.-C. Park, C. Choi, J.-P. Nam, T.-H. Kim, S.-K. Choi, J.-K. Park, J.-W. Nah, Anticancer effect of gene/peptide co-delivery system using transferrin-grafted LMWSC, Int. J. Pharm., 488, 165-173 (2015).
DOI
|
18 |
S. A. Vinores, Pegaptanib in the treatment of wet, age-related macular degeneration, Int. J. Nanomedicine, 1, 263 (2006).
|
19 |
E. Chiellini, R. Solaro, Biodegradable polymeric materials, Adv. Mater., 8, 305-313 (1996).
DOI
|
20 |
C. S. Brazel, S. L. Rosen, Fundamental principles of polymeric materials, John Wiley & Sons (2012).
|
21 |
S. A. Wickline, A. M. Neubauer, P. M. Winter, S. D. Caruthers, G. M. Lanza, Molecular imaging and therapy of atherosclerosis with targeted nanoparticles, J. Magn. Reson. Imaging, 25, 667-680 (2007).
DOI
|